Clinical Trial

Evaluation of Somatostatin Receptor Expression in PET 68Ga-DOTATOC in Patients Followed for Metastatic Breast Cancer

Study acronym: DOTABREAST
Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated March 4, 2025 (before its estimated October 2025 completion). Its status may not reflect the trial's current state.
Summary
DOTABREAST: Evaluation of Somatostatin Receptor Expression in PET 68Ga-DOTATOC in Patients Followed for Metastatic Breast Cancer This is a prospective, monocentric, non-controlled, non-randomized, open-label, interventional study.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-09-20; most recent amendment 2025-02-27.
Status change: Not Yet Recruiting → Recruiting 2025-01-24
Trial Details
NCT Number NCT06611891
Lead Sponsor University Hospital, Grenoble
Conditions Breast Cancer Metastatic
Enrollment 25 participants
Start Date 2025-01-06
Primary Completion 2025-10 (estimated)
Study Completion 2026-10 (estimated)
Updated on ClinicalTrials.gov 2025-03-04